{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE318nnn/GSE318387/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Methylation profiling"],"species":["Homo sapiens"],"gds_type":["Methylation profiling by array"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318387"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Promoter hypomethylation of cadherin-7: a novel epigenetic marker associated with cerebral small vessel disease","description":"Introduction: Cerebral small vessel disease (SVD), manifesting as white matter hyperintensities (WMH), lacunar infarctions, and cerebral microbleeds on MRI, has been linked to epigenetic alterations. Methods: Genome-wide promoter methylation was profiled using the Infinium MethylationEPIC v2.0 array in peripheral inflammatory cells from 16 patients without SVD and 16 patients with all three imaging features. Results: EPIC profiling identified 17 promoter regions with significant differences between groups, and CDH7 hypomethylation emerged as an independent predictor of SVD imaging features. Conclusion: CDH7 hypomethylation was identified and validated as an epigenetic marker predictive of MRI-defined SVD imaging features.","dates":{"publication":"2026/04/01"},"accession":"GSE318387","cross_references":{"GSM":["GSM9493614","GSM9493613","GSM9493612","GSM9493611","GSM9493618","GSM9493617","GSM9493616","GSM9493615","GSM9493619","GSM9493620","GSM9493603","GSM9493602","GSM9493601","GSM9493589","GSM9493600","GSM9493607","GSM9493606","GSM9493605","GSM9493604","GSM9493609","GSM9493608","GSM9493591","GSM9493590","GSM9493595","GSM9493594","GSM9493593","GSM9493592","GSM9493610","GSM9493599","GSM9493598","GSM9493597","GSM9493596"],"GPL":["33022"],"GSE":["318387"],"taxon":["Homo sapiens"],"PMID":["[41890232]"]}}